Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.

29 Mar 2010

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

Global home health management market expanding at CAGR of 10% through 2012

Remote health management is the fastest growing segment of a burgeoning home health management market. However, RHM’s full potential will materialize only if health insurers adopt reimbursement practices that encourage greater physician adoption, concludes Scientia Advisors, a global strategy consulting firm, in its review of the worldwide home health management market released today.

26 Mar 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

BioScrip acquires Critical Homecare Solutions Holdings

BioScrip, Inc. today announced that it has completed its acquisition of Critical Homecare Solutions Holdings, Inc. (“CHS”), a leading provider of home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions.

26 Mar 2010

Altuglas International launches new acrylic resins for medical devices applications

Altuglas International, a world leader in acrylic plastics, has expanded its family of Medical grade acrylic resins, with Altuglas® CR30 and Altuglas® CR50 impactmodified grades. These resins, feature exceptional alcohols and lipids resistance that reduces environmental stress cracking due to attack of aggressive drugs and disinfectants. These novel acrylic resins are designed for easy injection molding of complex multi-cavity parts.

25 Mar 2010

SCOLR Pharma's total revenue dips 2% in 2009, but significant improvements in operating expenses

SCOLR Pharma, Inc. today reported financial results for the twelve months ended December 31, 2009. The Company will host a live conference call on March 31, 2010, at 11:30 a.m. (Eastern Standard Time).

25 Mar 2010

FDA grants Orphan Drug Designation for anti-diabetic drug

The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.

24 Mar 2010

LPI's ANDA for Eszopiclone tablets receives tentative approval from USFDA

Lupin Pharmaceuticals, Inc. announced today that it has received tentative approval for the Company's Abbreviated New Drug Application for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration.

23 Mar 2010

DSM Biomedical expands resources and operations in the U.S. and Europe

DSM Biomedical, a global leader in biomedical materials science, today announced the expansion of its resources and operations in the United States and Europe to support the growing demand for the company’s portfolio of innovative polyurethanes for chronically implanted medical devices in the regions.

23 Mar 2010

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BioDelivery Sciences International, Inc. announced the positive outcome of a meeting with the FDA on the development program for BEMA Granisetron, the company’s potential treatment for the prevention of nausea and vomiting associated with cancer therapy. FDA concurred with BDSI’s plans to pursue a development program based on clinical pharmacokinetic data for a 505(b)(2) New Drug Application.

22 Mar 2010

StockPreacher.com releases investment report on A.P. Pharma

StockPreacher.com announces an investment report featuring A.P. Pharma Inc. (Nasdaq:APPA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

22 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Aston University scientists receive grants to develop new forms of drug delivery

Before you swallow a tablet, or put it into a glass of water to dissolve, do you ever stop and think about how it actually works in your body and how quickly and effectively it can deliver the drug to where it is needed?

22 Mar 2010

Team Consulting to provide Oval Medical Technologies new funds in exchange for equity

Leading medical technology firm Team Consulting has joined the consortium of investors that is providing seed funding to Oval Medical Technologies, a developer of proprietary medical pre-filled syringes and autoinjectors.

22 Mar 2010

Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out

Helix BioPharma Corp. announced today that it has achieved last-patient-out in its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts.

22 Mar 2010

SRI International researchers to disclose preliminary results of NTD detecting diagnostic at 239th ACS

SRI International, an independent nonprofit research and development organization, will present preliminary results of a diagnostic to detect neglected tropical diseases (NTDs) at the 239th National Meeting & Exhibition of the American Chemical Society (ACS) being held on March 21-25 in San Francisco.

22 Mar 2010

'Dipstick' 3-in-1 test for detection of Chagas' disease, leishmaniasis and African trypanosomiasis

A new simple, inexpensive three-in-one test to diagnose a terrible trio of parasitic diseases that wreak havoc in the developing world is passing preliminary tests, scientists reported here today. Described during the 239th National Meeting of the American Chemical Society the test is for Chagas' disease, leishmaniasis, and "sleeping sickness" or African trypanosomiasis.

22 Mar 2010

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting.

19 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Drug Delivery News and Research

Further Reading

Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Global home health management market expanding at CAGR of 10% through 2012

JCOM receives approval from KFDA to commercialize MuGard in Korea

BioScrip acquires Critical Homecare Solutions Holdings

Altuglas International launches new acrylic resins for medical devices applications

SCOLR Pharma's total revenue dips 2% in 2009, but significant improvements in operating expenses

FDA grants Orphan Drug Designation for anti-diabetic drug

LPI's ANDA for Eszopiclone tablets receives tentative approval from USFDA

DSM Biomedical expands resources and operations in the U.S. and Europe

BEMA Granisetron development program: BDSI announces positive meeting with FDA

StockPreacher.com releases investment report on A.P. Pharma

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Aston University scientists receive grants to develop new forms of drug delivery

Team Consulting to provide Oval Medical Technologies new funds in exchange for equity

Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out

SRI International researchers to disclose preliminary results of NTD detecting diagnostic at 239th ACS

'Dipstick' 3-in-1 test for detection of Chagas' disease, leishmaniasis and African trypanosomiasis

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News